Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for June 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Nora Pharma	NRA- Paroxetine	Paxil	PAROXETINE HCI HEMIHYDRATE	10 mg	tablet	02479753
Nora Pharma	NRA-Sildenafil	Viagra	SILDENAFIL CITRATE	100 mg	tablet	02476819
Sandoz Canada Inc.	Sandoz Clobetasol	Clobex Spray	CLOBETASOL PROPIONATE	0.05% w/w	topical solution spray	02495023
Teva Canada Limited	Teva- Teriparatide Injection	Forteo	TERIPARATIDE ACETATE	250 mcg/ml	SC solution- 2.4 mL prefilled pen	02486423
Natco Pharma (Canada) Inc.	Nat-Lanthanum	Fosrenol	LANTHANUM CARBONATE DIHYDRATE	500 mg	chewable tablet	02498758



Natco Pharma (Canada) Inc.	Nat-Lanthanum	Fosrenol	LANTHANUM CARBONATE DIHYDRATE	750 mg	chewable tablet	02498766
Natco Pharma (Canada) Inc.	Nat-Lanthanum	Fosrenol	LANTHANUM CARBONATE DIHYDRATE	1000 mg	chewable tablet	02498774
Accel Pharma Inc.	Accel- Pilocarpine	Salagen	PILOCARPINE HCI	5 mg	tablet	02496119